ArticleFrontiers in pharmacology2022
Application of an Accessible Interface for Pharmacokinetic Modeling and
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- PK-Informed Microphysiological Systems: From Dynamic Dosing to Quantitative In Vitro-In Vivo Translation.Pharmaceutics · 2026Review
- Democratizing Artificial Intelligence in Toxicology: Real-World Applications and Automated Computational Workflows.Chemical research in toxicology · 2026Review
- Re-Thinking Pharmacokinetics in Ovarian Cancer: What Do Organoids Add?International journal of molecular sciences · 2026Review
- Application of in vitro to in vivo extrapolation (IVIVE) to inform chemical health guidance value derivation-sample case studies comparing neuro-, hepato-, and developmental toxicities.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Phytochemical profiling and pharmacological evaluation ofFrontiers in pharmacology · 2026Article
- Advancing human health risk assessment: the role of new approach methodologies.Frontiers in toxicology · 2025Review
- Selective anti-cancer effects of cannabidiol and Δ9-tetrahydrocannabinol via PI3K/AKT/mTOR inhibition and PTEN restoration in ovarian cancer cells.Frontiers in pharmacology · 2025Article
- Article
- Community-Engaged Research and the Use of Open Access ToxVal/ToxRef In Vivo Databases and New Approach Methodologies (NAM) to Address Human Health Risks From Environmental Contaminants.Birth defects research · 2024Article
- Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling of Nanomaterials.ACS pharmacology & translational science · 2024Review
- Article
- Artificial intelligence (AI)-it's the end of the tox as we know it (and I feel fine).Archives of toxicology · 2024Review
- Investigating open access new approach methods (NAM) to assess biological points of departure: A case study with 4 neurotoxic pesticides.Current research in toxicology · 2024Article
- Applying new approach methodologies to assess next-generation tobacco and nicotine products.Frontiers in toxicology · 2024Review
- Key challenges for in vitro testing of tobacco products for regulatory applications: Recommendations for dosimetry.Drug testing and analysis · 2023Article
- In-Depth Analysis of Physiologically Based Pharmacokinetic (PBPK) Modeling Utilization in Different Application Fields Using Text Mining Tools.Pharmaceutics · 2022Review
- Analyzing the metabolic fate of oral administration drugs: A review and state-of-the-art roadmap.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Regulatory toxicology testing has traditionally relied on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.